膀胱内灌注rAd-IFNα/Syn3治疗高级别卡介苗难治或复发非肌层浸润性膀胱癌:一项II期随机研究
这项开放标签、多中心、平行组II期研究纳入43例高级别卡介苗难治或复发非肌层浸润性膀胱癌患者,随机1:1接受膀胱内rAd-IFNα/Syn3 1×10^11 vp/mL或3×10^11 vp/mL。40例接受治疗的患者中,14例(35.0%;90% CI,22.6%至49.2%)在初始治疗后12个月无高级别复发,两种剂量12个月无高级别复发生存相近。rAd-IFNα/Syn3耐受性良好,无4级或5级不良事件。
要点
- 40例接受rAd-IFNα/Syn3治疗的患者中14例(35.0%;90% CI,22.6%至49.2%)12个月无高级别复发。
- 两种剂量(1×10^11 vp/mL与3×10^11 vp/mL)的12个月无高级别复发生存相近。
- rAd-IFNα/Syn3耐受性良好,无4级或5级不良事件,无患者因不良事件停药。
核心结论
- rAd-IFNα/Syn3耐受性良好,对无法或不愿接受根治性膀胱切除术的卡介苗治疗后高级别非肌层浸润性膀胱癌患者显示出有前景的疗效。
研究设计与样本
- 开放标签、多中心(n=13)、平行组II期研究(ClinicalTrials.gov标识符:NCT01687244)。
- 43例高级别卡介苗难治或复发非肌层浸润性膀胱癌患者随机1:1接受膀胱内rAd-IFNα/Syn3 1×10^11 vp/mL或3×10^11 vp/mL。
- 第3、6、9个月有应答者在第4、7、10个月再次治疗。
- 主要终点为12个月无高级别复发生存;所有接受至少一剂的患者纳入疗效和安全性分析。
主要发现
- 2012年11月5日至2015年4月8日期间,40例患者接受rAd-IFNα/Syn3治疗(1×10^11 vp/mL组n=21;3×10^11 vp/mL组n=19)。
- 14例患者(35.0%;90% CI,22.6%至49.2%)在初始治疗后12个月无高级别复发。
- 两种剂量12个月无高级别复发生存相近。
- 14例患者中2例分别在治疗开始后21个月和28个月出现复发,1例在17个月时死于上尿路肿瘤且无复发。
- rAd-IFNα/Syn3耐受性良好,无4级或5级不良事件,无患者因不良事件停药。
临床怎么用
- 作者认为rAd-IFNα/Syn3对卡介苗治疗后无法或不愿接受根治性膀胱切除术的高级别非肌层浸润性膀胱癌患者显示出有前景的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd-IFNα/Syn3 (randomly assigned 1:1 to 1 × 1011 viral particles (vp)/mL or 3 × 1011 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results Forty patients received rAd-IFNα/Syn3 (1 × 1011 vp/mL, n = 21; 3 × 1011 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd-IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion rAd-IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
引用
- Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017. PMID: 28834453. doi:10.1200/JCO.2017.72.3064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。